David Andersen has represented a variety of companies, individuals, private equity funds and institutional clients in general corporate and securities matters, with an emphasis on the representation of emerging-growth high-technology and biotechnology companies. In this capacity, Mr. Andersen has assisted clients in structuring, developing and positioning numerous business enterprises for venture capital and private equity investment, growth through acquisitions and eventual sale or initial public offerings.

Mr. Andersen’s practice includes counseling clients in connection with all phases of the corporate life cycle, including issues related to initial formation and capitalization, public and private offerings of debt and equity securities, mergers and acquisitions, strategic alliances and joint ventures, and recapitalizations and corporate restructurings. Mr. Andersen regularly assists companies with the purchase and sale of stock or assets, mergers and other change of control transactions. In addition, Mr. Andersen has represented a number of public companies in diverse industries (including technology, healthcare, and entertainment) in all aspects of securities reporting and compliance, and advises clients with respect to a wide range of corporate governance issues, equity incentive plans and related matters.



Civic Involvement & Honors

    • “Who’s Who in Law” - Los Angeles Business Journal, 2011
    • Safe Cities Foundation - Director
    • Safe Cities Foundation - Director
Read More

Representative Experience

  • Representing the issuers and venture capital firms in numerous private placement financings in industries such as software, financial technology, digital health, gaming, social media and biotechnology
  • Numerous acquisitions and sales of public and private companies in industries such as software, hardware, telecom, financial technology, IT services, biotechnology and entertainment and new media
  • Representing significant shareholder in $3 billion sale of audio equipment and music streaming businesses
  • Representing the issuer in a $100 million venture capital investment and recapitalization transaction
  • Representing a manufacturing company in a cross-border restructuring, business combination and syndicated credit facility
  • Representing a medical group in a restructuring and spin-off transaction with a hospital chain
  • Representing a party to a merger of publicly traded healthcare companies and with respect to the related S-4 registration statement
  • Serving as issuer’s counsel in Rule 144A offerings, secondary public offerings, and the initial public offering of a technology company